| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In C2C12 myoblast differentiation, NNMTi (10-30 μM; 96 hours) causes a concentration-related increase in myoblast differentiation. Compared to untreated developed myoblasts (which produced 12% MHC-positive myotube nuclei), 30 μM NNMTi resulted in a 45% increase in myoblast differentiation, producing 18% MHC-positive myotube nuclei [1].
|
|---|---|
| ln Vivo |
NNMTi (subcutaneous injection; 5 mg/kg and 10 mg/kg; 2 weeks, 1 week prior to and 1 week following injury) increases the proliferation of muscle cells during the process of recovering from injury. The percentage of active muSCs was 60% and 75%, respectively. Under NNMTi therapy, the proportion of fibers containing EdU+ myonuclei rose by 40% and 48% at 5 mg/kg and 10 mg/kg, respectively. Control fused myonuclei had odds ratios of 0.58 and 0.53 times, respectively, the NNMTi low and high doses [2]. Mice administered with NNMTi (subcutaneous injection; 10 mg/kg; 1 week) did not exhibit systemic toxicity, and there was no difference in glucose, cholesterol, plasma protein, or electrolyte levels between the control and NNMTi-treated groups. In aged rats, repeated daily injection of NNMTi for one week following injury did not result in any negative behavioral effects or systemic toxicity [2].
|
| References |
|
| Molecular Formula |
C10H11IN2
|
|---|---|
| Molecular Weight |
286.1122
|
| Exact Mass |
285.996
|
| CAS # |
42464-96-0
|
| PubChem CID |
66522933
|
| Appearance |
Brown to reddish brown solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[I-].[N+]1(C)=CC=CC2=C(C=CC=C12)N
|
| InChi Key |
JPEZFBFIRRAFNR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10N2.HI/c1-12-7-3-4-8-9(11)5-2-6-10(8)12;/h2-7,11H,1H3;1H
|
| Chemical Name |
1-methylquinolin-1-ium-5-amine;iodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20.83 mg/mL (72.80 mM)
H2O: 2.27 mg/mL (7.93 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4952 mL | 17.4758 mL | 34.9516 mL | |
| 5 mM | 0.6990 mL | 3.4952 mL | 6.9903 mL | |
| 10 mM | 0.3495 mL | 1.7476 mL | 3.4952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
